Abnormal activation of the Janus kinase/signal transducer and activator of transcription （JAK/STAT） signaling pathway is involved in the pathogenesis of diffuse large B-cell lymphoma （DLBCL）. In recent years， inhibitors targeting JAK2 and STAT3 have emerged as promising therapeutic candidates in DLBCL. This review summarizes the efficacy and safety profiles of JAK2 inhibitors （e.g.， ruxolitinib） and STAT3 inhibitors （direct small-molecule inhibitors， the antisense oligonucleotide， and proteolysis targeting chimeras， etc.） in preclinical models and clinical trials. Accumulating evidence indicates that JAK2 and STAT3 inhibitors exhibit antitumor activity and are generally well tolerated in a subset of DLBCL patients. Meanwhile， the development of novel drug delivery systems has significantly enhanced the stability， bioavailability， and targeting ability of the compounds. Furthermore， JAK2 and STAT3 inhibitors may exhibit synergistic effects when combined with other therapy strategies （such as combinations with B-cell receptor signaling pathway inhibitors， immunomodulators， or other targeted drugs）. However， current clinical applications are still in their early stages. Future research should concentrate on precision treatment strategies based on the genetic subtyping of DLBCL， and further refine the delivery systems for inhibitors as well as combination drug regimens to improve clinical outcomes.

Objective:To explore the method and experience of augmentation mammoplasty with autologous fat transplantation assisted by external expander.Methods:From January 2013 to December 2020, 352 female patients (698 breasts, 346 bilateral and 6 unilateral), aged from 18 to 55 years, with an average age of 41.5 years, were admitted to the Department of Cosmetic Surgery, Beijing Jingmei Medical Cosmetology Clinic. From 1-28 days before surgery, autologous fat transplantation was performed after wearing the dilator, and postoperative wearing of the dilator lasted from 1 to 24 months, with an average of 3.5 months.Results:The volume of fat transplantation per breast ranged from 150 ml to 460 ml, with an average of 320 ml. No obvious postoperative complications such as fat liquefaction, infection, intramammary induration and fat embolism were observed, and the postoperative appearance was lasting. The postoperative follow-up was conducted from 6 months to 7 years, and patient postoperative satisfaction rate reached 84.9% and doctors＇ satisfaction after surgery reached 82.1%.Conclusions:Augmentation mammoplasty with autologous fat transplantation assisted by external expander can effectively improve the appearance of breast morphology and contour defects and increase the survival rate of fat transplantation, which is worthy of clinical application.

ObjectiveToanalyzethepathogensofsuppurativeendophthalmitis,theirdistributionanddrug susceptibility.Provide valuable information for the clinical options in effective use of antimicrobial agents.Methods Collected 259 cases of endophthalmitis from the patients with aqueous humor and vitreous fluid for pathogens and drug sensitivitytestinordertocarryontheanalysisoftheresults.Results 113casesofbacterialculturepositivein259 cases of specimens,with a detection rate of 43.63%.6 cases of multiple bacteria infection,and 2 case of fungal infec-tion.The total separation of pathogens was 120 strains.89 strains were gram positive coccus,accounting for 74.17%, 11 were gram positive bacillus strains, accounting for 9.17%, 13 strains of gram-negative bacilli, accounted for 10.83%,gram-negative in 5strains(4.17%),fungus in 2strains(1.67%).Conclusion Main pathogenic bacteria suppurative endophthalmitis is gram-positive, the pathogen species distribution and antimicrobial susceptibility of change should be timely monitored and the rational using of antibiotics can reduce the generation of drug-resistant strains.